Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03856788 · ClinicalTrials.gov registry record · Phase 4
Unilateral TAP Block for Laparoscopic Gastric Sleeve Surgery
A Phase 4 study of Laparoscopic Sleeve Gastrectomy and Subcostal Transversus Abdominis Plane Block, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03856788: Completed Phase 4 study of Laparoscopic Sleeve Gastrectomy and Subcostal Transversus Abdominis Plane Block, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03856788 is a Phase 4 study of Laparoscopic Sleeve Gastrectomy and Subcostal Transversus Abdominis Plane Block that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03856788, a Phase 4 study of Laparoscopic Sleeve Gastrectomy and Subcostal Transversus Abdominis Plane Block, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team will be assessing if the unilateral subcostal transversus abdominis plane (TAP) block can decrease pain and improve outcomes following laparoscopic sleeve gastrectomy surgeries.
Primary Outcome
Amount of intravenous (IV) opioid consumption within 24-hour period
Conditions Studied
Interventions
- DRUG Bupivacaine
- DRUG Saline
Study Locations (1)
New York
- Mount Sinai Brooklyn - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2021-03-25 |
| Phase | Phase 4 |
What the finished NCT03856788 record still lists
NCT03856788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Laparoscopic Sleeve Gastrectomy appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine is the first listed.
NCT03856788 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03856788 about?
NCT03856788 is a clinical study titled "Unilateral TAP Block for Laparoscopic Gastric Sleeve Surgery". The study team will be assessing if the unilateral subcostal transversus abdominis plane (TAP) block can decrease pain and improve outcomes following laparoscopic sleeve gastrectomy surgeries.
What is the current status of trial NCT03856788?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2018-12-10. Estimated completion is 2021-03-25.
What conditions does trial NCT03856788 study?
This clinical trial studies the following conditions: Laparoscopic Sleeve Gastrectomy, Subcostal Transversus Abdominis Plane Block.
What interventions are being tested in trial NCT03856788?
The interventions under investigation include: Bupivacaine (DRUG), Saline (DRUG).
Who is sponsoring clinical trial NCT03856788?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03856788 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Laparoscopic Sleeve Gastrectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03856788's enrollment target sits among peer trials
43 1371st of 2000 higher than 621 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI